Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the ...
Sarepta sinks 9% after Elevidys studies placed on hold in Europe
The shares are down 9%, or $5.53, to $56.94 in premarket trading. Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.